The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2021 | IMpower010: adjuvant atezolizumab improves DFS in resected stage II-IIIA NSCLC
Heather A. Wakelee, MD, Stanford University, Stanford, CA, talks on the findings of IMpower010, a Phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC). Adjuvant immune checkpoint blockade demonstrated disease-free survival (DFS) benefit with a safety profile consistent of atezolizumab monotherapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
Disclosures
Heather A. Wakelee, MD has received research funding from ACEA Biosciences, Arrys Therapeutics, AstraZeneca/Medimmune, BMS, Celgene, Clovis Oncology, Exelixis, Genentech/Roche, Gilead, Merck, Novartis, Pharmacyclics, Sea Gen, Xcovery; is on the advisory board (compensated) of AstraZeneca, Xcovery, Janssen, Daiichi Sankyo, Blueprint, Mirati, Helsinn; is on the advisory board (not compensated) of Merck Genentech/Roche; the president elect at IASLC; part of the executive committee at ECOG-ACRIN.
